ArticleFrontiers in bioinformatics2025
Subtractive genomic approach to uncover novel drug targets in
Article in Frontiers in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An integrated subtractive genomics and immunoinformatic approach for designing a multi-epitope peptide vaccine against methicillin-resistantFrontiers in bioinformatics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The rise of multidrug-resistant Methods: A subtractive genomics approach was used to identify essential, pathogen-specific proteins. A lead target was prioritized based on its druggability, localization, and network interactions. The target's 3D structure was then modeled for molecular docking, molecular dynamics (MD) simulations, and binding free energy calculations with a polyphenol library. Results: The screening identified UDP-N-acetylglucosamine transferase (MurG) as a promising and previously unexplored drug target. The polyphenol 6-prenylnaringenin showed a superior binding affinity for MurG compared to the antibiotic ciprofloxacin. Subsequent MD simulations and binding free energy calculations confirmed that the MurG-6-prenylnaringenin complex was significantly more stable. Conclusion: This study validates MurG as a druggable target in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.